Trial Profile
A Randomised, Double Blind Study to Evaluate the Safety and Efficacy of the p38 Kinase Inhibitor, GW856553, in Subjects With Neuropathic Pain From Lumbosacral Radiculopathy
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 30 Jun 2023
Price :
$35
*
At a glance
- Drugs Losmapimod (Primary)
- Indications Neuropathic pain
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline; GSK
- 10 Sep 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 26 Apr 2010 New trial record